Sanofi has announced positive Phase 2 results for lunsekimig, a bispecific antibody designed to simultaneously block TSLP and IL-13, in two respiratory studies. The AIRCULES Phase 2b study met its primary and key secondary endpoints in moderate-to-severe asthma, demonstrating statistically significant reductions in exacerbations and improvements in lung function.
The DUET Phase 2a study also met primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, showing improvements in nasal polyp scores, nasal congestion, and CT imaging. However, an exploratory Phase 2b study called VELVET in atopic dermatitis did not meet its primary endpoint, though it showed improvements in secondary skin clearance measures.
Across all studies, lunsekimig demonstrated acceptable tolerability with similar adverse event rates between treatment and placebo groups. Phase 3 studies dubbed PERSEPHONE and THESEUS are ongoing, positioning the dual-target approach as a potentially differentiated option in respiratory medicine.